Search
for
Sort by
Research 31–60 of 1000+
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- The JAK/STAT signaling pathway: from bench to clinic
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
- JAK Inhibitors for Treatment of Alopecia Areata
- Alopecia Areata: Current Treatments and New Directions
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Treatment of pediatric alopecia areata: A systematic review
- Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- A phase 2a trial of brepocitinib for cicatricial alopecia
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Application of Baricitinib in Dermatology
- Under Development JAK Inhibitors for Dermatologic Diseases
- Alopecia areata – Current understanding and management
- Janus kinase inhibitors for alopecia areata
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Baricitinib for the Treatment of Alopecia Areata
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata